Register to chat with like-minded investors on our interactive forums.
Period:
Draw Mode:
| Volume | 7,557 |
|
|||||
| News | - | ||||||
| Day High | 3.085 | Low High |
|||||
| Day Low | 2.95 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Tharimmune Inc | THAR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.03 | -0.97% | 3.05 | 11:25:42 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 3.00 | 2.95 | 3.085 | 3.08 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 324 | 7,557 | $ 3.03 | $ 22,891 | - | 2.75 - 142.50 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 11:30:10 | 1 | $ 3.07 | USD |
Tharimmune Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 35.22M | 11.74M | - | 0 | -9.32M | -0.79 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
Tharimmune News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical THAR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 3.51 | 3.77 | 2.75 | 3.17 | 173,633 | -0.46 | -13.11% |
| 1 Month | 5.5935 | 6.00 | 2.75 | 4.53 | 265,175 | -2.54 | -45.47% |
| 3 Months | 6.60 | 7.461 | 2.75 | 5.49 | 227,382 | -3.55 | -53.79% |
| 6 Months | 7.65 | 8.55 | 2.75 | 6.51 | 482,772 | -4.60 | -60.13% |
| 1 Year | 82.50 | 142.50 | 2.75 | 55.27 | 1,255,357 | -79.45 | -96.30% |
| 3 Years | 82.50 | 142.50 | 2.75 | 55.27 | 1,255,357 | -79.45 | -96.30% |
| 5 Years | 82.50 | 142.50 | 2.75 | 55.27 | 1,255,357 | -79.45 | -96.30% |
Tharimmune Description
| Hillstream BioPharma Inc is a biotechnology company developing novel therapeutic candidates targeting ferroptosis, an emerging new anti-cancer mechanism resulting in iron-mediated cell death for drug-resistant and devastating cancers. |
